| Cash Flow | 2025-08-31 | 2025-05-31 |
|---|---|---|
| Net loss | -665,318 | -331,451 |
| Fda clinical trial expenses paid directly by s.r. burzynski m.d., ph.d | 493,250 | 254,255 |
| Prepaids | 400 | 700 |
| Accounts payable | 6,926 | 8,665 |
| Accrued liabilities | 21,492 | 20,088 |
| Net cash used by operating activities | -144,050 | -49,143 |
| Contribution of capital | 144,134 | 49,117 |
| Net cash provided by financing activities | 144,134 | 49,117 |
| Net increase (decrease) in cash | 84 | -26 |
| Cash and cash equivalents at beginning of period | 847 | - |
| Cash and cash equivalents at end of period | 931 | - |
BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
BURZYNSKI RESEARCH INSTITUTE INC (BZYR)